Scholarlink

<p>Nano-azurin is redox-active protein has recently attracted attention as potential multifunctional therapeutics, primarily in infectious disease and cancer. This review highlights its potential against <i>Campylobacter</i> spp., including antibiotic resistant variants, in addition to anticancer properties. Campylobacteriosis is a serious public health problem worldwide because of its zoonotic potential and the increasing antimicrobial resistance (AMR) rates as well as its relationship with gastrointestinal carcinogenesis. Nano-azurin not only affects microbial viability and biofilm formation, but also stimulates host immune responses. In cancer settings, it specifically binds to neoplastic cells inducing apoptosis and preventing tumor growth. In particular, a nanoformulation can enhance the stability of the drug, its bioavailability and its selective delivery by lowering systemic toxicity. Moreover, nano-azurin regulates innate immunity functions contributing to the elimination of pathogens and the immune surveillance of tumours. The dual-action profile is promising, though several obstacles with respect to large-scale manufacturing, pharmacokinetics behaviours and clinical translation are important. In summary, nano-azurin is a new nanobiotherapeutic platform at the cross between antimicrobial therapy and cancer immunotherapy, which shows great promise for treatment of malignancies related to infections.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Targeting Campylobacter infection using nano-azurin: innate immune reprogramming and anticancer implications

  • 期刊论文

  • 发表日期：

    2026年7月8日

查看全文
  • Othman Abdulrahman Mohammed,
  • Farhang Hameed Awlqadr,
  • Aryan Mahmood Faraj,
  • Syamand Ahmed Qadir,
  • Sonia Morya,
  • Mohammed N. Saeed

摘要

Nano-azurin is redox-active protein has recently attracted attention as potential multifunctional therapeutics, primarily in infectious disease and cancer. This review highlights its potential against Campylobacter spp., including antibiotic resistant variants, in addition to anticancer properties. Campylobacteriosis is a serious public health problem worldwide because of its zoonotic potential and the increasing antimicrobial resistance (AMR) rates as well as its relationship with gastrointestinal carcinogenesis. Nano-azurin not only affects microbial viability and biofilm formation, but also stimulates host immune responses. In cancer settings, it specifically binds to neoplastic cells inducing apoptosis and preventing tumor growth. In particular, a nanoformulation can enhance the stability of the drug, its bioavailability and its selective delivery by lowering systemic toxicity. Moreover, nano-azurin regulates innate immunity functions contributing to the elimination of pathogens and the immune surveillance of tumours. The dual-action profile is promising, though several obstacles with respect to large-scale manufacturing, pharmacokinetics behaviours and clinical translation are important. In summary, nano-azurin is a new nanobiotherapeutic platform at the cross between antimicrobial therapy and cancer immunotherapy, which shows great promise for treatment of malignancies related to infections.